Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Emily Seal

Physician Assistant Petoskey, MI Physician Assistant

NPI 1922381995 CMS profile 11002811

560 W Mitchell Street, Petoskey, MI 49770

Open in the dashboard

General payments

$5,405

130 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emily Seal of Petoskey, MI is reported in the CMS Open Payments database as having received $5,405 across 130 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,426 12
2024 General $562 23
2023 General $603 25
2022 General $834 29
2021 General $981 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emily Seal
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Emily Seal were reported at $2,426. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Emily Seal Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $981 $132 $37–$438 $132
2022 $834 $155 $48–$522 $149
2023 $603 $167 $52–$557 $160
2024 $562 $178 $55–$600 $164
2025 $2,426 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Insulet Corporation $2,401 24 payments
  2. AstraZeneca Pharmaceuticals LP $1,508 50 payments
  3. Novo Nordisk Inc $620 22 payments
  4. Lilly USA, LLC $212 11 payments
  5. Sanofi-Aventis U.S. LLC $206 11 payments
  6. Tandem Diabetes Care, Inc. $123 2 payments
  7. Amgen Inc. $104 3 payments
  8. Corcept Therapeutics $100 1 payment
  9. Bayer HealthCare Pharmaceuticals Inc. $73 3 payments
  10. Medtronic, Inc. $35 2 payments
  11. Other $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,397 122 payments
  2. Travel and Lodging $1,997 7 payments
  3. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. Omnipod $2,401 24 payments
  2. FARXIGA $1,464 47 payments
  3. Ozempic $306 14 payments
  4. RYBELSUS $236 13 payments
  5. SOLIQUA 100/33 $150 8 payments
  6. t:slim X2 Insulin Pump with Control-IQ $123 2 payments
  7. Wegovy $120 6 payments
  8. Korlym $100 1 payment
  9. JARDIANCE $84 4 payments
  10. TEPEZZA $76 1 payment
  11. Other $503 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

4,221

Median for Physician Assistant: 241

Drug cost

$3,927,376

Median for Physician Assistant: $4,110

Branded share of claims

84.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 757 $979,592
Ozempic Semaglutide Brand 447 $658,458
Korlym Mifepristone Brand 12 $518,111
Farxiga Dapagliflozin Propanediol Brand 336 $377,534
Jardiance Empagliflozin Brand 259 $321,346
Trulicity Dulaglutide Brand 171 $199,569
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 123 $146,140
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 138 $136,152
Tresiba Flextouch U-200 Insulin Degludec Brand 127 $123,702
Omnipod Dash Pods (Gen 4) Insulin Pump Cart,cont Inf,bt Brand 50 $62,164

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $132
$132 336 —
Wegovy
  • Novo Nordisk Inc $50
$50 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $44
$44 — —
ZEPBOUND
  • Lilly USA, LLC $28
$28 — —
RYBELSUS
  • Novo Nordisk Inc $19
$19 37 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record